DPI formulations for high dose applications - Challenges and opportunities.

This opinion piece gives reasons for high dose DPI applications, points out challenges and shows opportunities and possible solutions for high dose DPI. This piece of work shall set the stage for more in-depth reviews of state of the art and research papers addressing the challenges of high dose DPI which shall be included in the special issue of IJP.

[1]  Jürgen Seitz,et al.  Efficient Elimination of Inhaled Nanoparticles from the Alveolar Region: Evidence for Interstitial Uptake and Subsequent Reentrainment onto Airways Epithelium , 2007, Environmental health perspectives.

[2]  D. Morton,et al.  The role of force control agents in high-dose dry powder inhaler formulations. , 2009, Journal of pharmaceutical sciences.

[3]  Xiaoxue Bai,et al.  An update on the use of rifapentine for tuberculosis therapy , 2014, Expert opinion on drug delivery.

[4]  R. Vanbever,et al.  Delivery strategies for sustained drug release in the lungs. , 2014, Advanced drug delivery reviews.

[5]  P. V. Wichert,et al.  Möglichkeiten und Probleme der Applikation von systemisch wirksamen, höhermolekularen Wirkstoffen mittels Inhalation* , 2006, Medizinische Klinik.

[6]  P. Seville,et al.  Sustained delivery by leucine-modified chitosan spray-dried respirable powders. , 2009, International journal of pharmaceutics.

[7]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[8]  H. Chan,et al.  Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Abdelwahab Omri,et al.  Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients. , 2015, The Journal of antimicrobial chemotherapy.

[10]  P. Colombo,et al.  Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. , 2014, International journal of pharmaceutics.

[11]  S. Bihari,et al.  Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum. , 2008, Journal of postgraduate medicine.

[12]  J. Zhao,et al.  Nanocrystals embedded in chitosan‐based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Yun-Seok Rhee,et al.  Nanomedicine in pulmonary delivery , 2009, International journal of nanomedicine.

[14]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[15]  H. Smyth,et al.  Carrier-free high-dose dry powder inhaler formulation of ibuprofen: Physicochemical characterization and in vitro aerodynamic performance. , 2016, International journal of pharmaceutics.

[16]  H. Frijlink,et al.  5 Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept ( Twincer ® ) for high powder doses , 2009 .

[17]  M. Hindle,et al.  Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design , 2015, Annals of Biomedical Engineering.

[18]  H. Chan,et al.  Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis , 2015, Drug development and industrial pharmacy.

[19]  R. Norton,et al.  Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases. , 2016, Journal of pharmaceutical sciences.

[20]  J. Zhao,et al.  Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[21]  T. Block,et al.  Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice , 2017, AAPS PharmSciTech.

[22]  E. Fattal,et al.  Pulmonary drug delivery systems for tuberculosis treatment. , 2015, International journal of pharmaceutics.

[23]  A. Hickey,et al.  Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs. , 2015, Molecular pharmaceutics.

[24]  I. Kellaway,et al.  Novel sustained release microspheres for pulmonary drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Gerhard Scheuch,et al.  Clinical perspectives on pulmonary systemic and macromolecular delivery. , 2006, Advanced drug delivery reviews.

[26]  C. Flodin,et al.  Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry. , 2015, Journal of pharmaceutical sciences.

[27]  J. Weers,et al.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. , 2011, Journal of aerosol medicine and pulmonary drug delivery.

[28]  Michael Yianneskis,et al.  Drug delivery to the respiratory tract using dry powder inhalers , 1994 .

[29]  A. Hickey,et al.  Dry powder inhaler formulation. , 2005, Respiratory care.

[30]  P. Young,et al.  From single excipients to dual excipient platforms in dry powder inhaler products. , 2016, International journal of pharmaceutics.

[31]  G. Döring,et al.  Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study , 2012, Thorax.

[32]  P. Young,et al.  A review of co-milling techniques for the production of high dose dry powder inhaler formulation , 2017, Drug development and industrial pharmacy.

[33]  A. Hickey,et al.  Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery , 2009, Pharmaceutical Research.

[34]  A Population Dose–Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects , 2017, CPT: pharmacometrics & systems pharmacology.

[35]  J. Patton,et al.  Good Things in Small Packages: an Innovative Delivery Approach for Inhaled Insulin , 2017, Pharmaceutical Research.

[36]  B. Laube,et al.  The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. , 2005, Respiratory care.

[37]  I. Gonda,et al.  Development of Liposomal Ciprofloxacin to Treat Lung Infections , 2016, Pharmaceutics.

[38]  F. Ahsan,et al.  Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[39]  D. Köhler.  Aerosols for systemic treatment , 2007, Lung.

[40]  W. Seeger,et al.  Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome(.). , 2016, Current pharmaceutical design.

[41]  Hailong Zhang,et al.  Improvement of pulmonary absorption of poorly absorbable macromolecules by hydroxypropyl-β-cyclodextrin grafted polyethylenimine (HP-β-CD-PEI) in rats. , 2015, International journal of pharmaceutics.

[42]  Yan Fang,et al.  Epsilon-poly-L-lysine guided improving pulmonary delivery of supramolecular self-assembled insulin nanospheres. , 2015, International journal of biological macromolecules.

[43]  D. Geller.  Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. , 2005, Respiratory care.

[44]  K. McKeage.  Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis , 2013, Drugs.

[45]  N. Rasenack,et al.  In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate. , 2003, International journal of pharmaceutics.

[46]  P. Russo,et al.  Chimeral agglomerates of microparticles for the administration of caffeine nasal powders , 2004 .

[47]  B. Button,et al.  Optimising inhaled mannitol for cystic fibrosis in an adult population , 2015, Breathe.

[48]  M Hoppentocht,et al.  Technological and practical challenges of dry powder inhalers and formulations. , 2014, Advanced drug delivery reviews.

[49]  P. Young,et al.  Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate , 2017, AAPS PharmSciTech.

[50]  J. Staniforth,et al.  Active and intelligent inhaler device development. , 2004, International journal of pharmaceutics.

[51]  Newton,et al.  Influence of Relative Humidity of Storage Air on the Adhesion and Autoadhesion of Micronized Particles to Particulate and Compacted Powder Surfaces , 1997, Journal of colloid and interface science.

[52]  M. Konstan,et al.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[53]  R. Dalby,et al.  Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers , 2000, AAPS PharmSci.

[54]  Shirui Mao,et al.  Recent advances in controlled pulmonary drug delivery. , 2015, Drug discovery today.

[55]  S. Colman,et al.  Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. , 2007, The American journal of medicine.

[56]  J. Weers,et al.  The PulmoSphere™ platform for pulmonary drug delivery. , 2014, Therapeutic delivery.

[57]  N. Kunda,et al.  Pulmonary Delivery of Proteins Using Nanocomposite Microcarriers. , 2015, Journal of pharmaceutical sciences.

[58]  S. Waldman,et al.  The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[59]  A. Kim,et al.  Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  TrainiDaniela,et al.  Overcoming Dose Limitations Using the Orbital® Multi-Breath Dry Powder Inhaler , 2014 .

[61]  S. Newman,et al.  Principles of metered-dose inhaler design. , 2005, Respiratory care.

[62]  A. Yu,et al.  CFD-DEM study of the aerosolisation mechanism of carrier-based formulations with high drug loadings , 2017 .

[63]  Y. Lai,et al.  Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery , 2009, Nanoscale research letters.

[64]  P. York,et al.  Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation , 1998 .

[65]  G. P. Martin,et al.  The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. , 2000, International journal of pharmaceutics.

[66]  A. Chuchalin,et al.  Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial , 2013, Current medical research and opinion.

[67]  David F. Fletcher,et al.  Influence of Air Flow on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses , 2005, Pharmaceutical Research.